Login to Your Account



Trius Antibiotic Tedizolid Hits Phase III Endpoints vs. Zyvox

By Trista Morrison
Staff Writer

Tuesday, December 20, 2011
Trius Therapeutics Inc. hit all primary and secondary endpoints in its first Phase III trial of antibiotic tedizolid (formerly torezolid), yet investors rewarded the San Diego biotech by pushing its shares down 12 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription